Endocrinology

Anuradha Krishnan, BA, research analyst at dQ&A, previews her presentation at the 2025 American Diabetes Association Scientific Sessions, sharing findings from a multi-country survey examining how...

Lois E. Donovan, MD, and Denice Feig, MD, MSc, FRCPC, discuss their presentation at the 2025 American Diabetes Association Scientific Sessions, previewing results of a randomized multicenter study which...

Nestoras Mathioudakis, MD, MHS, shares findings from a randomized controlled trial comparing a fully automated, app-based diabetes prevention program with a standard CDC-recognized intervention,...

In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...

A study presented at the 85th Scientific Sessions of the American Diabetes Association explored how physical and cognitive limitations affect glucometer use in adults aged 65 years and older with type 2...

For patients with type 2 diabetes and established cardiovascular or kidney disease, daily oral semaglutide significantly lowered the risk of major adverse cardiovascular events during a median of 49.5...

A study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Orlando, FL examines skin conditions and foot ulcers in patients in Nepal with endocrine disorders and...

A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...

Despite unchanged treatment modalities for over 75 years, contemporary management of Graves’ disease increasingly centers on preserving thyroid function, with methimazole emerging as the preferred...

Recent updates in endocrinology reveal fezolinetant as a promising non-hormonal treatment for menopausal symptoms and tirzepatide’s impressive 93% risk reduction in progression from prediabetes to type 2...